Grifols (GIKLY) Change in Account Payables (2010 - 2020)
Grifols (GIKLY) posted Change in Account Payables of -$25.7 million for Q1 2020, up 67.14% quarter-over-quarter from -$78.2 million in Q4 2019, and up 53.91% year-on-year from -$16.7 million in Q2 2019.
Grifols (GIKLY) Change in Account Payables (2010 - 2020) Analysis & Trends
Grifols (GIKLY) has reported Change in Account Payables for 10 consecutive years, with -$25.7 million the latest figure, recorded in Q1 2020.
- Change in Account Payables for Q1 2020 came in at -$25.7 million, up 53.91% year-over-year; the trailing twelve-month figure through Mar 2020 was -$155.5 million (down 134.7% YoY), and the FY2025 annual result was $109.4 million, up 253.09% from the prior year.
- Change in Account Payables was -$25.7 million for Q1 2020 at Grifols, up from -$78.2 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $81.5 million in Q4 2016 and troughed at -$78.2 million in Q4 2019.
- Average Change in Account Payables over 5 years is -$5.2 million, with a median of $4.2 million recorded in 2018.
- Year-over-year, Change in Account Payables soared 128.83% in 2016 and slumped 1957.3% in 2019.
- Over 5 years, Change in Account Payables stood at $81.5 million in 2016, then sank by 40.67% to $48.3 million in 2017, then slumped by 91.29% to $4.2 million in 2018, then plunged by 1957.3% to -$78.2 million in 2019, then jumped by 67.14% to -$25.7 million in 2020.
- Per Business Quant data, the three most recent Change in Account Payables figures were -$25.7 million in Q1 2020, -$78.2 million in Q4 2019, and -$55.8 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 571.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -67.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -25.70 Mn |
| Mar 31, 2020 | -25.70 Mn |
| Dec 31, 2019 | -78.22 Mn |
| Dec 31, 2019 | -78.22 Mn |
| Mar 31, 2019 | -55.77 Mn |
| Mar 31, 2019 | -55.77 Mn |
| Dec 31, 2018 | 4.21 Mn |
| Dec 31, 2018 | 4.21 Mn |
| Jun 30, 2018 | -22.71 Mn |
| Jun 30, 2018 | -22.71 Mn |
| Mar 31, 2018 | 8.02 Mn |
| Mar 31, 2018 | 8.02 Mn |
| Dec 31, 2017 | 48.35 Mn |
| Dec 31, 2017 | 48.35 Mn |
| Jun 30, 2017 | 34.54 Mn |
| Jun 30, 2017 | 34.54 Mn |
| Mar 31, 2017 | 19.09 Mn |
| Mar 31, 2017 | 19.09 Mn |
| Dec 31, 2016 | 81.49 Mn |
| Dec 31, 2016 | 81.49 Mn |